Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.
Holmusk is a provider of healthcare data and technology solutions to support the treatment of mental health and chronic diseases.
Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins.
Poseida Therapeutics is a biopharmaceutical company utilizing gene engineering capabilities to develop targeted therapeutics.
Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
A platform technology that is revolutionising healthcare by increasing the accessibility and diagnostic capability of non-invasive testing
RxLightning automates the manual enrollment process of starting a patient on specialty medications.
Flare Therapeutics is a biotech startup that creates precision therapies for cancer and other disorders by targeting transcription factors.
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
Bringing clarity to cancer. Working to ensure that everyone touched by cancer has a clear path to the right care.
Orionis Biosciences operates in the healthcare industry focusing on biotechnology business & innovation.
Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.
Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy.
Koneksa Health is a healthcare data analytics company that helps researchers incorporate emerging technologies into their clinical studies.
Transforming medical data into predictive algorithms without code
NuvoAir is a value-based specialty management platform transforming the diagnosis and management of chronic heart and lung conditions.
SiO2 Materials Science is a plastic container designing company.
Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.
Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity.
Kedalion Therapeutics is a biotechnology company that develops and commercializes transformative topical ophthalmic therapies.
Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip.
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.
Science 37 is a clinical research company that facilitates universal participation in clinical trials for patients and providers.
Novartis has invested in 99 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Novartis's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 30 different industry categories.
Among tracked funding rounds, SiO2 Materials Science received $205.0M in a Debt Financing round. Novartis's total known invested capital is $3.8B.
Novartis's average investment size is $60.5M across its portfolio of 99 companies.
Recent Novartis portfolio additions include Aravax, Holmusk, Hyku, Poseida Therapeutics, Caribou Biosciences. These companies were founded in 2020 or later.